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Prostate cancer (CaP) is the most common malignancy in North American men and represents the second most 
common cause of cancer death.  CaP is characterized by many different stages including very aggressive forms that 
disseminate to bone, lymph nodes, and other tissues.  The host’s immune system plays a central role in the ability of 
tumors to obtain nutrients and oxygen.  Tumors release factors that attract and activate cells of the immune system 
including macrophages.  Macrophages have well-defined roles as agents that participate in inflammation and that 
help us fight infections, but the biological significance of tumor-associated macrophages (TAMs) is unclear (Elgert 
et al., 1998). When macrophages are recruited to tumor sites complex cancer-macrophage interactions take place 
(Joseph and Isaacs, 1998; Satoh et al., 2003). The biological result of these interactions depends on the changes that 
occur within macrophages, the physical location reached by these cells as they encounter the tumor, and the type of 
malignancy.  In some tumors, including CaP, macrophages can both stimulate and inhibit cancer growth and 
proliferation (Shimura et al., 2000).  One of the phenotypic changes that take place when macrophages are exposed 
to specific stimuli is the transcriptional activation of a gene encoding a phospholipase A2, platelet-activating factor 
acetylhydrolase (PAF-AH) (Stafforini et al., 1990).  This enzyme has anti-inflammatory properties owing to its 
ability to hydrolyze a large group of bioactive lipids including platelet-activating factor (PAF), oxidized 
phospholipids and esterified isoprostanes with varied and potent biological functions (Stafforini et al., 2003; 
Stafforini et al., 2006). The levels of PAF-AH mRNA, which provides a mechanism to down-regulate bioactive lipid 
signaling, are altered during CaP progression compared to normal prostate tissues.  The PAF-AH mRNA detected in 
these analyses likely originates from macrophages recruited to CaP sites.  The goal of this proposal was to 
investigate whether PAF-AH present in CaP sites reflected participation of this enzyme and its substrates in the 
pathogenesis of the disease.  To address this issue, we used mice (known as TRAMP mice) that spontaneously 
develop CaP owing to overexpression of an oncogene in the prostate gland exclusively.  We made these animals 
deficient in PAF-AH by crossing them to our PAF-AH knockout animals.  Using this and related model systems we 




UPREGULATION OF PAF-AH IS RECAPITULATED IN THE TRAMP MODEL OF PROSTATE CANCER   We first 
generated an animal model suitable to test the hypotheses posed.  This model capitalized on the availability of mice 
engineered to develop CaP and mice in which the PAF signaling pathway was exacerbated owing to impaired 
degradation.  Once we obtained a suitable number of animals of the desired genotype, we investigated whether this 
model recapitulated the upregulation of PAF-AH observed in authentic human CaP samples.  This was a key issue to 
address because the premise of the project was based on observations in human CaP that might not have been 
reproducible in a murne model of the disease.  We found that PAF-AH activity increased during development in 











































































Fig. 1.  PAF-AH activity in plasma and prostate tissues from TRAMP mice during CaP 
progression.  A,  PAF-AH activity and protein levels were determined in plasma samples of 
TRAMP mice of various ages.  B, Extracts from grossly-uninvolved dorsolateral prostate glands 
were assayed for PAF-AH activity and protein content.  
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plete at 10-20 weeks of age and 
 
GENETIC ABLATION OF PAF-AH DECREASES SURVIVAL IN A MURINE MODEL OF PROSTATE CANCER.  In 
igure 3.  Partial and complete 
metastatic disease in the lymph nodes or lungs is present in 100% of the animals by 28 weeks of age (Gingrich et al., 
1996).  Thus, in this model, upregulation of PAF-AH expression in serum and in prostate tissues occurs with a 
relatively long latency period compared to that of tumor development.  Since the PAF-AH activity determined in 
tissue extracts likely reflects contributions from calcium independent phospholipases A2 including the intracellular 
paralog of PAF-AH, we determined the levels PAF-AH protein in uninvolved dorsolateral prostate samples and in 
prostate tumors, using immunoblot analyses.  We found (Fig 2, A-B) that the expression of PAF-AH increased with 
time and that the tumors expressed higher levels of PAF-AH compared to prostate tissues that were uninvolved as 
judged by gross examination.  Note the different amounts of protein subjected to electrophoresis in the experiments 
depicted in Figs. 2, A-B.  In related studies we found PAF-AH expression in plasma remains constant throughout the 
life of the mouse (not shown).  This result established that the TRAMP model recapitulated human CaP in terms of 
upregulation of PAF-AH expression.  We then proceeded to develop the remaining tasks of the proposal by 
investigating if a causal relationship existed between PAF-AH expression and disease severity utilizing in vivo 










N   N        T     T     N     N     T      T
A B










fulfillment of experiments proposed in the original proposal we utilized mice deficient in the expression of the 
secreted (plasma) form of PAF-AH.  These animals develop normally but have enhanced susceptibility to 
inflammation, a feature also observed in PAF-AH-deficient human subjects (Stafforini et al., 2003; Stafforini et al., 
1999; Stafforini et al., 1996).  To 
investigate whether PAF-AH functionally 
affected CaP, we generated TRAMP mice 
harboring three different genotypes at the 
PAF-AH locus.  We found (Fig. 3) that 
haploinsufficiency and complete 
deficiency of PAF-AH had a significant 





deletion of PAF-AH decreases the 
survival of TRAMP mice.  TRAMP 
animals that were wild-type, partially-
deficient, or homozygous deficient for 
PAF-AH were allowed to develop until 
they died spontaneously or reached 
criteria for euthanasia.   
 
 
Fig. 2.  PAF-AH expression in grossly uninvolved prostate and prostate tumor tissues from TRAMP mice 
ng CaP progression A, Dorsolateral prostate gland extracts from TRAMP mice (75 g) were subjected to dur .  
immunoblot analysis using anti-PAF-AH and anti- -actin antibodies.  B, Same as A) using extracts (7.5 g) from 





his observation suggested a functional association between PAF-AH expression and one or more parameters 
XPRESSION OF THE PAFR IN PROSTATE TISSUES AND IN CELL LINES.  The ability of PAF and OxPL to elicit 
 resulted from 
ig. 5.  PAF stimulates cellular proliferation in CaP cells.  TRAMP-C2 
 
T
important in prostate tumorigenesis.  The precise nature of these signals is unknown, but our results suggested that 
accumulation of substrates inactivated by PAF-AH such as PAF and OxPL contributed to the observed effects.  We 
previously reported that PAF-AH expression is transcriptionally-activated by PAF and OxPL (Cao et al., 1998).  
Thus, our results support the hypothesis that the upregulation of PAF-AH in CaP is a compensatory mechanism 




signals requires expression of PAFR and coupling to G-proteins.  We investigated the expression of PAFR in 
prostate tissues and in cell lines.  First, we found that PAFR is moderately upregulated at the mRNA level in human 
CaP, and that its upregulation is associated with disease progression (Fig. 4A).  Second, we found that three CaP cell 
lines derived from TRAMP mice express primarily a monomeric (48 KDa) form of PAFR (Fig. 4B).  
In addition, we detected larger species whose molecular mass was 96 KDa and that appeared to have
dimerization of PAFR or formation of a complex with another protein(s) or receptor(s) (Fig. 4B).  Thirdly, extracts 
from dorsal (D) and ventral (V) prostate glands from TRAMP mice also expressed PAFR in monomeric (48 KDa) 
and 96 KDa forms (Fig. 4C).  Deletion of the PAF-AH gene did not significantly affect the expression levels of 
monomeric PAFR.  In contrast, the 96 KDa form was upregulated primarily in the dorsal prostate of PAF-AH 
deficient mice (Fig. 4C).  
To investigate whether PAFR expressed in CaP cells was functional, we 
subjected TRAMP-C2 cells to a non-hydrolyzable analog of PAF (carbamoyl 
PAF, cPAF).  We found (Fig. 5) that treatment of TRAMP-C2 cells with 1 
nM cPAF, a concentration that reflected the levels of the natural ligand, 
increased the rate of proliferation with relatively fast kinetics compared to 
other cancer cell lines [(Melnikova et al., 2006), Fig 5].  These results 
demonstrated the functional integrity of PAFR expressed in TRAMP cells and 
supported the hypothesis that stimulation of the PAF axis contributes to 




cells were exposed to cPAF for 24 hours and cellular proliferation was 
assessed by the XTT assay.   
 
Fig. 4  Expression of PAFR in human and mouse CaP cells and tissues.  A, Human PAF-AH mRNA 
levels in benign prostate specimens and in CaP and metastatic CaP samples.  Data reproduced from 
Oncomine TM.  B, Total cell lysates from TRAMP-C1, C2, and C3 cells (50 g) were subjected to 
immunoblot analyses using anti-PAFR and anti-actin antibodies.  C, Extracts (50 g) of dorsal (D)  and 
ventral (V) prostate tissues from TRAMP mice of various ages and PAF-AH genotypes were treated as in 
B.  N.S.: non-specific. 
12               31                49               26        34                52          Age,
weeks
PAF-AH -/+
Benign            CaP Metastatic
n=23               n=64      CaP (n=25)
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IGNALING EVENTS.  In the next series of experiments we investigated the expression and/or state of activation of 
ells PAF activates mitogen-activated protein kinase modules such as p38 MAPK, JNK and 
 




KEY RESEARCH ACCOMPLISHMENTS RELEVANT TO THIS REPORT 
  Established dissection, biochemical and immunological assays necessary for the execution of the study 
ing CaP development  
nitial data 
 included 
 proposal that was submitted to the Department 
S
select molecules previously identified as downstream effectors of PAF-mediated effects.  PAF mediates angiogenic 
responses, in part, by increasing the expression of vascular endothelial growth factor (VEGF) (Ahmed et al., 1998).  
VEGF is considered to be the most important contributor to induction and maintenance of the neovasculature in 
tumors (Kim et al., 2002).  We investigated whether CaP cells express VEGF using a model system that consisted of 
three TRAMP cell lines derived from a prostate tumor from a single 32-week-old TRAMP mouse (Foster et al., 
1997) and protein extracts from CaP tumors.  The antibody we utilized (sc-507, Santa Cruz Biotechnology) was 
raised a region of VEGF-A (amino acids 1-140) that shares sub-domains of identity with other members of the 
VEGF superfamily, including VEGF-B,-C, and –D.  Thus, it is likely that this antibody recognizes multiple 
members of the VEGF superfamily.  Our results suggested that at least two forms of VEGF [-A (M r= 21KDa) and –
C (Mr = 46.5 KDa)] are expressed in TRAMP cell lines (Fig. 5).  Tumors from TRAMP-PAF-AH-/- transgenic mice 
expressed immunoreactive species whose size was consistent with the presence of VEGF-C (Mr = 46.5 KDa) and -D 
(Mr = 40.9 KDa).  These results suggested that when the function of PAF-AH is ablated and ligands of PAFR 
accumulate, enhanced synthesis and release of VEGF-C and -D by CaP cells stimulate angiogenesis and/or 
lymphangiogenesis.   
In colonic epithelial c
ERKs (Wang and Chakrabarty, 2003).  We observed that deletion of PAF-AH did not alter the extent of JNK or p38 
MAPK activation in TRAMP mice (not shown).  ERK was constitutively-activated in the three TRAMP lines (Fig. 
6).  In TRAMP mice, ERK phosphorylation seemed to occur at an earlier time in tumors from PAF-AH deficient 
mice compared to wild-type TRAMP animals (Fig. 6).  These results suggested that activation of the PAF axis 
contributes to increased growth through the ERK pathway in CaP cells.  
F
in TRAMP cell lines and in tumors 
from TRAMP mice.  Total cell lysates 
from TRAMP-C1, C2, and C3 cells (50 
g, left panel) or extracts  of prostate 
tumors excised from TRAMP mice of 
various ages and PAF-AH genotypes (35 
g, right panel) were subjected to 
immunoblot analyses using antibodies 






  Generated genetically-engineered animals with the genotypes required for the execution of the study 
  Investigated expression of PAF-AH in the plasma of TRAMP transgenic animals  
  Obtained evidence for modulation of PAF-AH expression in the prostate gland dur
  Observed decreased lifespan of mice that lack expression of PAF-AH during CaP development. 
  Initiated analysis of tumor formation within the context of PAF-AH deletion and generated i
suggesting increased severity of tumor formation and metastasis induced by PAF-AH deficiency. 
  Complemented animal studies with molecular analyses in prostate epithelial and CaP cells.  These
demonstration of functional PAF receptor expression, altered levels of VEGF upon deletion of PAF-AH in 
vivo and ERK activation in response to PAF-AH deletion 
  Generated the framework upon which the PI crafted a new
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PAF-AH +/+ PAF-AH -/-
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REPORTABLE OUTCOMES 
Presentations:  This work has been presented on several occasions in our institution where it is open for discussion 
bstract: An abstract was submitted and selected for poster presentation in the upcoming IMPaCT meeting to take 
nimal models: As a consequence of our work, a new line of mice has been generated that harbors the TRAMP 
CONCLUSIONS 
The results we have generated during the tenure of this grant used both cellular and in vivo approaches.  Our studies 
“So what” section:  the experimental design of our studies was based on the need to define what types of patients 
 
and subject to input and criticism from colleagues, trainees, and students.  Moreover, portions of this work were 
presented by the PI to scientists at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil.   
 
A
place September 5-8, 2007 in Atlanta, GA. 
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transgene developed by Dr. Greenberg and his group and in which one or two PAF-AH alleles are deleted.  These 




suggested that the PAF signaling pathway contributes to the pathogenesis of CaP by modulating cellular growth and 
metastatic events.  In the absence of PAF-AH, the severity of the CaP increases and is accompanied by a higher 
incidence of metastatic events and faster tumor growth.  Conversely, phenotypic alterations that lead to elevated 
expression of PAF-AH and thus result in silencing of signals elicited by bioactive lipid mediators through the PAF 
receptor may inhibit growth and/or promote apoptosis.  In the setting of CaP, this phenotype is consistent with a 
model of recruitment and activation of macrophages by inflammatory stimuli, resulting in the localized release of a 
PAF-AH activity which may serve to blunt the actions of bioactive lipids such as PAF.  Our data strongly support 
out initial hypothesis, that is, that PAF-AH deficiency exacerbates CaP and that the increased levels of this enzyme 
observed in human CaP and in animal models of the disease represent a compensatory mechanism in response to 
accumulated PAF and other ligands of the PAF receptor.  The approaches we utilized were complementary in nature, 
included both human and murine systems, utilized an animal model with proven resemblance to the human disease, 
and were internally consistent.  The impact of our work at the present moment lies primarily on having identified a 
novel player in CaP pathogenesis.  The implications of this work relate to our contribution to understanding the 
etiology of this disease and the possibility that this pathway may offer a number of interventional approaches.  
 
would potentially benefit the most from this work.  The use of the animal model we developed and utilized here 
ensured that various phases of CaP development were represented.  This feature allowed us to establish that PAF 
signaling is likely to play a role during early stages of CaP and that the results of PAF-mediated signaling increase 
the rate of metastatic progression.  This information will help us define the subset of CaP patients who would benefit 
the most from potential targeted therapies in the future.  There may also be diagnostic applications generated from 
the results of these studies.  Because it is possible to measure the levels of PAF-AH in blood and presumably in 
prostate biopsies, we will be able to identify the levels of this protein in patients using clinical assays and genetic 
tests.  This will allow us to investigate if altered functioning of this gene can become one of the tools in our 
diagnostic kit and whether PAF or PAF-AH can be used to assess clinical CaP and predict risk.  Thus, the clinical 
applications that could result from the work proposed here have both diagnostic (assessment of gene and protein 
status in CaP patients) and interventional (i.,e, administration of recombinant protein or receptor antagonists) 
applications.  Therapies aimed at inhibiting CaP growth or spreading by targeting this pathway alone or in 
combination with others, could be developed.  For example, the use of gene-modified macrophage therapy treatment 
using intratumor injection of PAF-AH-transduced macrophages could be considered as a complement to existing 
therapies using IL-12-transduced macrophages (Satoh et al., 2003).  Finally, new potential targets for intervention 
within this lipid-signaling pathway can be identified.  For example, inhibition of the synthetic enzymes involved in 
PAF biosynthesis would offer an additional attractive possible target for intervention.  And, inhibition of lipid 
oxidative reactions that can generate ligands for the PAF receptor such as oxidized phospholipids, could also be 
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